Analyst Price Targets — BRNS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 13, 2025 11:07 am | Yi Chen | H.C. Wainwright | $3.00 | $1.15 | TheFly | Barinthus Biotherapeutics price target lowered to $3 from $5 at H.C. Wainwright |
| June 13, 2024 12:13 pm | Yi Chen | H.C. Wainwright | $5.00 | $1.87 | TheFly | Barinthus Biotherapeutics price target lowered to $5 from $8 at H.C. Wainwright |
| June 13, 2024 5:29 am | Carter Gould | Barclays | $3.00 | $1.90 | TheFly | Barinthus Biotherapeutics price target lowered to $3 from $7 at Barclays |
Latest News for BRNS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (the “Company”) (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Upon consummation of the transaction, Barinthus shareholders will own only 34.33% of the combined company. KSF is seeking…
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company's corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BRNS.
U.S. House Trading
No House trades found for BRNS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.